Active, not recruiting
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
- Conditions
- Breast Cancer, Early Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
- Locations
-
- Research Site Dothan, Alabama, United States
- Research Site Phoenix, Arizona, United States
- Research Site Tucson, Arizona, United States
- Research Site Fayetteville, Arkansas, United States